About Us
About Us
Company Profile
Zhejiang Ausun Pharmaceutical Co., Ltd.. was established in April 2010 and was listed on the Shanghai Stock Exchange on May 9, 2017, with the stock code 603229.
The company is located in the Taizhou Bay Economic and Technological Development Zone of Zhejiang Province and is a national high-tech enterprise. Currently, the company has established a national postdoctoral workstation, Zhejiang Provincial Key Enterprise Research Institute, Provincial Enterprise Technology Center, Provincial R&D Center, and other platforms.
The company mainly engages in the research, production, and sales of pharmaceutical preparations, specialty raw materials, and key pharmaceutical intermediates, as well as providing customized processing and R&D services for customers. Its products are mainly exported to Europe, America, Japan, South Korea, and other countries and regions.
The company's products are mainly divided into eight categories: liver diseases, respiratory system, cardiovascular and cerebrovascular, high-end fluorine products, prostaglandins, antibacterial, gout, and antitumor. The developed products have complex chiral structures, high R&D difficulty, strong technical barriers, and unique production processes. The company attaches great importance to technological innovation and R&D. In the past three years, R&D investment has accounted for more than 10% of operating income.
The company focuses on the health industry, always adhering to the core philosophy of "Quality + Innovation," with the corporate mission of "Serving Health, Creating the Future Together." Following the requirements of China's pharmaceutical industry "14th Five-Year" plan and national innovation development strategy, and guided by the development philosophy of "Talent and Win-Win," it aims to build a research and innovation system with new drug creation capabilities and internationally leading generic drug technology. At the same time, it continuously expands the coverage of its sales network, actively exploring high-end regulated markets such as the United States, Japan, and Europe, striving to become a globally competitive specialty pharmaceutical company in the future.
The company focuses on the health industry, always adhering to the core philosophy of "Quality + Innovation," with the corporate mission of "Serving Health, Creating the Future Together." Following the requirements of China's pharmaceutical industry "14th Five-Year" plan and national innovation development strategy, and guided by the development philosophy of "Talent and Win-Win," it aims to build a research and innovation system with new drug creation capabilities and internationally leading generic drug technology. At the same time, it continuously expands the coverage of its sales network, actively exploring high-end regulated markets such as the United States, Japan, and Europe, striving to become a globally competitive specialty pharmaceutical company in the future.
No. 5, East Fourth Avenue, Linhai Park, Zhejiang Chemical API Base, Zhejiang Province
No. 21, East Eighth Avenue, Linhai Park, Zhejiang Chemical API Base, Zhejiang Province
Email:
Company Address:
No.5, Donghai 4th Avenue, Zhejiang Chemical Materials Base Linhai Zone, Taizhou,Zhejiang,China
